The receptor preference of influenza viruses.
OBJECTIVE
The cell surface receptor used by an influenza virus to infect that cell is an N-acetyl neuraminic acid (NANA) residue terminally linked by an alpha2,3 or alpha2,6 bond to a carbohydrate moiety of a glycoprotein or glycolipid. Our aim was to determine a quick and technically simple method to determine cell receptor usage by whole influenza A virus particles.


METHODS
We employed surface plasmon resonance to detect the binding of viruses to fetuin, a naturally occurring glycoprotein that has both alpha2,3- and alpha2,6-linked NANA, and free 3'-sialyllactose or 6'-sialyllactose to compete virus binding. All virus stocks were produced in embryonated chicken's eggs.


RESULTS
The influenza viruses tested bound preferentially to NANAalpha2,3Gal or to NANAalpha2,6Gal, or showed no preference. Two PR8 viruses had different binding preferences. Binding preferences of viruses correlated well with their known biological properties.


CONCLUSIONS
Our data suggest that it is not easy to predict receptor usage by influenza viruses. However, direct experimental determination as described here can inform experiments concerned with viral pathogenesis, biology and structure. In principle, the methodology can be used for any virus that binds to a terminal NANA residue.
Meng
Bo
B
Department of Biological Sciences, University of Warwick, Coventry, UK. b.meng@warwick.ac.uk
Marriott
Anthony C
AC
Dimmock
Nigel J
NJ
D000818:Animals; D002642:Chick Embryo; D006801:Humans; D009980:Influenza A virus / Q000502:physiology*; D011485:Protein Binding; D011991:Receptors, Virus / Q000737:chemistry* / Q000378:metabolism*; D020349:Surface Plasmon Resonance; D053585:Virus Attachment; D000509:alpha-Fetoproteins / Q000737:chemistry / Q000378:metabolism
D011991:Receptors, Virus; D000509:alpha-Fetoproteins
Virology. 1997 Jun 23;233(1):224-34
9201232
J Virol. 1998 Sep;72(9):7367-73
9696833
Glycoconj J. 2007 Dec;24(9):583-90
17624609
Nature. 2006 Mar 23;440(7083):435-6
16554799
Virology. 2006 Oct 10;354(1):80-90
16876846
J Biol Chem. 1985 Jun 25;260(12):7362-7
3997874
Virology. 1997 Jan 20;227(2):493-9
9018149
Virus Res. 2007 Nov;129(2):175-81
17714820
Virus Res. 2005 Dec;114(1-2):15-22
15996787
Respir Res. 2007 Oct 25;8:73
17961210
J Biol Chem. 1979 Feb 10;254(3):789-95
83994
Virology. 1992 Aug;189(2):525-33
1641979
Mol Ther. 2001 Mar;3(3):395-402
11273782
Annu Rev Microbiol. 1973;27:101-17
4356530
J Virol. 2007 Jul;81(13):6890-8
17459930
Science. 2006 Apr 21;312(5772):399
16556800
J Virol. 2006 Aug;80(15):7469-80
16840327
J Virol. 2005 Jan;79(2):1113-24
15613339
J Virol. 2006 Aug;80(16):8060-8
16873262
J Biol Chem. 1991 Dec 15;266(35):23660-9
1748643
Glycobiology. 2007 Jul;17(7):713-24
17389652
Virus Res. 2007 Jun;126(1-2):9-18
17313986
Acta Histochem Suppl. 1990;40:35-8
2091044
Vaccine. 2006 May 15;24(20):4290-6
16621180
J Biol Chem. 1985 Feb 10;260(3):1362-5
3838173
Science. 2004 Mar 19;303(5665):1838-42
14764886
Virology. 1996 Mar 15;217(2):452-8
8610436
Proc Natl Acad Sci U S A. 2004 Mar 30;101(13):4620-4
15070767
J Virol. 2000 Sep;74(18):8502-12
10954551
Virology. 1989 Nov;173(1):317-22
2815586
Virol J. 2007 May 09;4:42
17490484
Glycoconj J. 2006 Feb;23(1-2):101-6
16575527
Nat Med. 2007 Feb;13(2):147-9
17206149
Virology. 2003 Sep 1;313(2):473-80
12954214
Virology. 1992 Jul;189(1):121-31
1376537
J Mol Biol. 2008 Sep 19;381(5):1382-94
18672252
Mol Biol (Mosk). 2002 May-Jun;36(3):542-9
12068641
Virology. 1999 Jun 5;258(2):232-9
10366560
J Virol. 1997 Apr;71(4):3357-62
9060710
J Virol. 2008 Sep;82(17):8570-8
18579602
Science. 2009 Jul 24;325(5939):484-7
19574347
Virology. 1998 Feb 1;241(1):101-11
9454721
J Virol. 2007 May;81(10):5181-91
17344280
Vaccine. 1995;13(15):1468-73
8578828
Am J Pathol. 2007 Oct;171(4):1215-23
17717141
J Virol. 2005 Sep;79(17):11533-6
16103207